Study in mice suggests drug could bring new benefits in treating depression by lifting mood within hours, plus offer sustained effectiveness
For someone with depression in the midst of a crisis, there is no time to waste. Yet time is exactly what currently-available antidepressants require to take effect—often on the order of weeks.
A new study suggests a fast-acting antidepressant may be on the horizon. In mice, the drug produces evidence of a mood lift within 24 hours and then continues working for sustained relief.
“What makes this study unique and exciting is that in the same drug we seem to have both of the properties you want in an antidepressant—both rapid and sustained effects,” said Jeffery Talbot, Ph.D., director of the Research Center on Substance Abuse and Depression at Roseman University of Health Sciences and one of the study’s lead investigators.
Though many drugs are currently available to treat people with depression, existing drugs do not work quickly, and they do not work for everyone. “Many people with depression simply don’t respond to available medications,” said Talbot. “There’s still a real need for new antidepressants.”
The drug, referred to by Talbot as its coded name MI-4 and better known among scientists as Ro-25-6981, has been shown by previous researchers to cause a rapid antidepressant effect in animals by blocking one of the brain’s signaling chemicals. But until now, researchers were not aware of the full spectrum of its antidepressant properties.
The new study bolsters the evidence for MI-4’s rapid effect and adds an exciting twist: MI-4 also works in the long term. Moreover, it may accomplish its long-term effects through a three-pronged approach known as triple reuptake inhibition, which refers to a drug’s ability to simultaneously increase the levels of three key chemicals in the brain that are known to affect mood and feelings of pleasure—dopamine, norepinephrine and serotonin. Most depression drugs only target one of these chemicals, which may explain why they are not effective in all patients.
The researchers found MI-4 via “virtual screening,” a method that uses computer modeling to find drugs that are likely to interact with particular receptors in the brain. “From looking at its structure, one would never have guessed that this drug interacts with the same monoamine transporter proteins as does Paxil or cocaine, but it does. That speaks to the ‘needle in a haystack’ detection power of the virtual screening methodology,” said Christopher Surratt, Ph.D., a professor of pharmacology working on this aspect of the study at Duquesne University.
Following the virtual screening, the researchers tested MI-4’s effects in cell cultures and then in mice. In addition to providing new evidence of its antidepressant properties, the study shows MI-4 would be unlikely to become addictive.
Depression is one of the most common mental illnesses in the world, affecting about 20 million people in the United States. Causing persistent sadness and loss of energy, it can take an enormous toll on a person’s ability to work or have healthy personal relationships and is a leading cause of suicide.
Antidepressants are some of the most commonly prescribed medications, with 264 million prescriptions written for antidepressants in 2011 totaling more than $11 billion in sales.
The Latest on: Antidepressant
via Google News
The Latest on: Antidepressant
- Thousands of antidepressants prescribed on the NHS in England for children as young as 5on March 4, 2021 at 11:41 pm
Thousands of antidepressants are being prescribed for children as young as five on the NHS - with the number growing each year, official figures show. The data for England, provided in a ...
- NHS doctors giving antidepressants to kids as young as FIVEon March 4, 2021 at 11:40 am
Thousands of antidepressants are being prescribed for children as young as five on the NHS with the number growing each year, official figures show.
- Successful Medical Applications of Psilocybin Help Erode Harmful Stigmason March 4, 2021 at 1:00 am
An example of a recent study includes data based on an examination of 27 people, which found that a treatment featuring the hallucinogen psilocybin worked better than the usual antidepressant ...
- Ion Channel in Brain May Serve as Novel Target for Treating Depressionon March 3, 2021 at 9:00 pm
Opening the KCNQ2/3 type of potassium channels in the brain is associated with significant improvements in depressive symptoms and anhedonia in patients with depression.
- Mind Medicine: Great Potential But Questionable Business Modelon March 3, 2021 at 10:24 am
MindMed's CEO has sold almost 25% of his shares in recent months, but the underlying fundamental potential is enormous if the company steers in the right direction.
- Researchers identify brain ion channel as new approach to treating depressionon March 2, 2021 at 9:17 pm
Researchers from the Icahn School of Medicine at Mount Sinai have identified a drug that works against depression by a completely different mechanism than existing treatments. Their study showed that ...
- Global Antidepressant Drugs Market Size, Share, Industry Report, Trends, Growth and Forecast 2020-2027on March 1, 2021 at 5:39 pm
Global Antidepressant Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast: 2018-2024 Overview: Depression is a serious mental illness affecting more than 350 million people ...
- Antidepressant Use in Pregnancy Can Affect Newbornon February 27, 2021 at 4:00 pm
These drugs, which include Zoloft, Prozac, and others, are widely considered to be the safest type of antidepressant medication to take during pregnancy. Its been difficult to confirm their safety ...
- Zydus Cadila gets USFDA nod for antidepressant drugon February 25, 2021 at 12:00 am
Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Nortriptyline Hydrochloride capsules USP, in strengths of 10 mg, 25 mg, 50 mg and 75 mg, ...
- Activation of BDNF by transcription factor Nrf2 contributes to antidepressant-like actions in rodentson February 24, 2021 at 7:58 am
The transcription factor erythroid 2-related factor 2 (Nrf2) and brain-derived neurotrophic factor (BDNF) play a key role in depression. However, the molecular mechanisms underlying the crosstalk ...
via Bing News